[go: up one dir, main page]

Shu et al., 2022 - Google Patents

Progress of triazole antifungal agent posaconazole in individualized therapy

Shu et al., 2022

View PDF
Document ID
15154559253862241355
Author
Shu Y
Shi Y
Yang Y
Dong Z
Yi Q
Shi H
Publication year
Publication venue
Journal of Clinical Pharmacy and Therapeutics

External Links

Snippet

What is known and objective Posaconazole is the second‐generation triazole antifungal agent with widespread clinical application. Posaconazole exposure is influenced by various factors such as drug interactions, disease state and diet, resulting in a high interindividual …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Liu et al. Emerging new targets for the treatment of resistant fungal infections
Groll et al. Posaconazole: clinical pharmacology and potential for management of fungal infections
Nett et al. Antifungal agents: spectrum of activity, pharmacology, and clinical indications
Petraitis et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration-and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis
Ashbee et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Shu et al. Progress of triazole antifungal agent posaconazole in individualized therapy
Li et al. Pharmacokinetic/pharmacodynamic profile of posaconazole
Smith et al. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations
Miyakis et al. Voriconazole concentrations and outcome of invasive fungal infections
Odds et al. Antifungal agents: mechanisms of action
Petraitiene et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia
Bandara et al. Fluconazole resistance in Candida albicans is induced by Pseudomonas aeruginosa quorum sensing
Autmizguine et al. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications
Lass‐Flörl et al. In vitro susceptibility testing in fungi: a global perspective on a variety of methods
Groll et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations
Cornely et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
Calugi et al. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002–2010)
Kontoyiannis A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines
Galgóczy et al. In vitro antifungal activity of phenothiazines and their combination with amphotericin B against different Candida species
Liston et al. Antifungal activity of gepinacin scaffold glycosylphosphatidylinositol anchor biosynthesis inhibitors with improved metabolic stability
Paiva Macedo et al. Antifungal resistance: why are we losing this battle?
Saini et al. Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy
Guinea et al. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections
Lewis Antifungal therapeutic drug monitoring
Druseikis et al. The metabolism of susceptibility: Clearing the FoG between tolerance and resistance in Candida albicans